替格瑞洛在行经皮冠状动脉介入治疗的急性冠状动脉综合征患者中的效果分析

Effect of ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention

目的探讨对ACS(急性冠状动脉综合征)患者在实施PCI(经皮冠状动脉介入)治疗期间给予替格瑞洛治疗的可行性。方法选择本院2015年6月至2017年5月收治的66例ACS患者作为实验对象;随机数表法分组后明确各组治疗药物;参照组33例:采用氯吡格雷药物治疗;研究组33例:采用替格瑞洛药物治疗;最终对比用药结果。结果用药前,两组ACS患者在血小板抑制率方面差异无统计学意义;用药后,同参照组ACS患者对比,研究组血小板抑制率获得明显提升(P<0.05);同参照组ACS患者不良事件发生率(12.12%)对比研究组(6.06%),差异无统计学意义。结论临床针对ACS患者在实施PCI治疗期间,替格瑞洛药物的有效应用,同氯吡格雷药物应用效果对比,可以使得血小板抑制率获得显著提升,并且不会导致不良事件发生率提升,从而对于ACS患者的成功治疗奠定基础。

Objective To investigate the feasibility of ticagrelor in patients with ACS(acute coronary syndrome)during PCI(percutaneous coronary intervention).Methods 66 patients with ACS admitted to our hospital from June 2015 to May 2017 were selected as experimental subjects.The randomized number table method was used to identify the treatment drugs in each group.The reference group(33 cases)was treated with clopidogrel.Study group(33 cases):treatment with ticagrelor;final comparison of medication results.Results Before administration,there was no significant difference in platelet inhibition rate between the two groups.After treatment,the platelet inhibition rate of the study group was significantly improved compared with the reference group(P<0.05).There was no significant difference in the incidence of adverse events(12.12%)between the ACS patients and the study group(6.06%).Conclusion The effective application of ticagrelor in patients with ACS during PCI is the same as that of clopidogrel,which can significantly increase the platelet inhibition rate without increasing the incidence of adverse events.Lay the foundation for successful treatment of ACS patients.